GSK is set to announce Q3 results, with forecasts of 8.00 billion pounds in turnover and a net profit decrease to 1.78 billion pounds. Concerns remain about vaccine sales, particularly for Arexvy and Shingrix, due to weak U.S. demand.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing